Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Operation Warp Speed For Rare Diseases? US FDA Is Considering Pilot Programs

Executive Summary

CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.

You may also be interested in...



Product Differences Necessitate Some US FDA Inconsistency In Rare Diseases, Center Directors Say

Development standards for a one-time gene therapy should be different from a drug taken regularly, CBER Director Peter Marks says.

US FDA’s Cell/Gene Therapy Office Looks To Improve Clarity Of Advice Through Written Responses

Standardizing the process for providing clarifications following sponsor meetings, particularly with regard to the written response-only format, is one of several solutions being piloted by the Office of Tissues and Advanced Therapies as part of its ‘growth program,’ which aims to expedite advances in cell/gene therapies while also improving staff satisfaction.

US FDA May Rethink White Oak Campus As Agency Plots ‘New Normal’ For Work

A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel